Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: A population approach

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1616-1624

  Xu, Lu ^a   Lu, Tong ^a   Tuomi, Lisa ^a   Jumbe, Nelson ^a   Lu, Jianfeng ^a   Eppler, Steve ^a   Kuebler, Peter ^a   Damico Beyer, Lisa A ^a   Joshi, Amita ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN A;

AGED; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED DRUG RELEASE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; IC 50; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; VITREOUS BODY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; FEMALE; HALF-LIFE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; VITREOUS BODY;

EID: 84875435647     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10260     Document Type: Article

References (40)

1. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26:859-870.
2. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology. 2010;117:1124-1133. e1121.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
4. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65. e55.
5. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-1112. e1101.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
7. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
8. LUCENTIS (ranibizumab injection). Highlights of prescribing information. Available at: http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf. Accessed April 15, 2011.
9. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-1266.
10. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726-733.
11. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007; 114:2179-2182.
12. Maurice DM. Flow of water between aqueous and vitreous compartments in the rabbit eye. Am J Physiol. 1987;252: F104-F108.
13. Katakam M, Ravis WR, Golden DL, Banga AK. Controlled release of human growth hormone following subcutaneous administration in dogs. Int J Pharm. 1997;152:53-58.
14. Wagner JG. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J Pharm Sci. 1983;72:838-842.
15. Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392-1403.
16. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-2668.
17. Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol. 1997;44:135-138.
18. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med. 1967;126:207-221.
19. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:633-642. e634.
20. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration. Year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124:1532-1542.
21. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623-632. e621.
22. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
23. Lowe J, Maia M, Wakshull E, et al. Development of a novel homogenous electrochemiluminescence assay for quantitation of ranibizumab in human serum. J Pharm Biomed Anal. 2010; 52:680-686.
24. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62:779-786.
25. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Population Pharmacokinetics. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 1999.
26. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001; 28:481-504.
27. Hart WM Jr. Adler's Physiology of the Eye. 9th ed. St. Louis, MO: Mosby-Year Book; 1992.
28. Bender B, Gaudreault J, Damico L, et al. A pharmacokinetic model describing ocular and systemic distribution of Lucentis in rabbits and monkeys. Poster presented at: Annual Meeting of the American Association of Pharmaceutical Scientists; November 11-15, 2007; San Diego, CA.
29. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20.
30. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85:425-430.
31. Cook DM, Biller BM, Vance ML, et al. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:4508-4514.
32. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877-1884.
33. Csaky KG, Gordiyenko N, Rabena MG, Avery RL. Pharmacokinetics of intravitreal bevacizumab in humans. Presented at: Annual Meeting of The Association for Research in Vision and Ophthalmology; May 6-10, 2007; Ft. Lauderdale, FL. Abstract 4936.
34. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26:1236-1260.
35. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393-401.
36. Morris PE, Zeno B, Bernard AC, et al. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. Crit Care. 2012;16:R31.
37. Larson SM. Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P. Pendergrass New Horizons Lecture. Radiology. 1987;165:297-304.
38. Brambell FW, Hemmings WA, Morris IGA. Theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-1354.
39. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res. 2002;25:97-113.
40. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.